ArisGlobal has announced significant growth and innovation in the first half of 2025, driven by its LifeSphere NavaX platform.

LifeSphere NavaX is a game-changer for the pharmaceutical industry, allowing companies to operationalize AI and automate safety operations. Seven global pharma companies are now leveraging NavaX across their safety operations, indicating growing confidence in GenAI-powered automation.

The platform has been adopted by top-tier companies, including a recent deployment at a Top 10 global pharma, which reported significant efficiency gains and strong early data accuracy within weeks of go-live. Another major player, Boehringer Ingelheim, successfully implemented NavaX for safety case intake, achieving 90% data accuracy within weeks.

The company has also signed the EU AI Pact, a key step in its commitment to responsible AI innovation. This initiative promotes ethical, transparent, and regulation-ready AI deployment across the industry. According to Jason Bryant, VP of Product Management, AI & Data at ArisGlobal,

Inspired by

• https://ai-techpark.com/arisglobal-reports-strong-growth-and-innovation-in-h1-2025/